OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated ...

SkyQuest projects that the Global Gene Therapy Market will reach a value of USD 38.34 Billion by 2031, with a CAGR of 19% during the forecast period (2024-2031).Numerous factors are responsible for ...

In this thought leader article Orjana Terova, Melisa Carpio, Ian Flaherty, Robin Butler, Nico Tuason, and Christine Gebski from Repligen describe how disruptive technologies are improving efficiency ...

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated ...

providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica's world-class capabilities ...

They can employ either recombinant viruses, such as adenovirus, adeno-associated virus (AAV), retrovirus, or lentivirus, or non-viral platforms, such as lipid nanoparticles, to transport the chosen ...